Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2025-03-30 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm Tianjian CPA Firm for the 2024 audit of Jiangsu Deyuan Pharmaceutical Co., Ltd. It discusses the appointment, qualifications, and audit work performed by the accounting firm, including their independence and compliance with auditing standards. The document does not contain the full audit report or financial statements but rather an assessment of the auditor's performance and their audit process. The length is relatively short (1562 characters), and it is a standalone report about the audit firm's duties and evaluation, not the full annual report or audit report itself. This fits the definition of an Audit Report / Information (AR) which includes standalone audit reports and related information about audit procedures and results, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2024
2025-03-30 Chinese
2024年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2024 Annual Equity Distribution Plan Announcement" from Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the company's proposed profit distribution plan including cash dividends and stock dividends (high send-transfer plan). It references audited financial results from the 2024 annual report but does not contain the full financial statements or comprehensive financial data itself. The document also includes legal compliance statements, shareholder meeting resolutions, and dividend policy explanations. The length is about 4100 characters, which is relatively short and consistent with an announcement rather than a full report. The document is clearly an announcement of a dividend distribution plan (equity distribution plan) and not the full annual report or earnings release. Therefore, it fits best under the category "Notice of Dividend Amount (DIV)" which covers announcements of dividend amounts, payment dates, and related details for shareholders.
2025-03-30 Chinese
投资者关系活动记录表
Regulatory Filings Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details an online meeting held on specific dates with various investors and company representatives. The content includes a presentation summary by the company's deputy general manager and financial officer, covering company overview, business, R&D, and operational performance, followed by Q&A. There are no financial statements or detailed financial data, nor is this a transcript of a conference call or an earnings release. It is a record of an investor relations event, not a formal investor presentation document or a full report. Given the nature of the document as a record of investor relations activities, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2025-03-17 Chinese
投资者关系活动记录表
Regulatory Filings Classification · 95% confidence The document is titled as an "Investor Relations Activity Record" from Jiangsu Deyuan Pharmaceutical Co., Ltd. It details a specific investor relations event held on March 6, 2025, including participants, questions asked, and company responses about business performance, product development, and approvals. The content is a Q&A format from an investor relations meeting rather than a formal financial report or earnings release. It does not contain financial statements or comprehensive financial data. The document length is short (1582 characters) and it is a record of an investor relations activity rather than a report or announcement of voting results, management changes, or capital updates. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and investor relations disclosures that do not fit other categories.
2025-03-09 Chinese
持股5%以上股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from a company regarding a shareholder holding more than 5% of shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares to be sold, the method and timing of the sale, compliance with relevant laws and regulations, and risk disclosures. This type of document is a notification about a major shareholding change, specifically a reduction in shares held by a significant shareholder. It does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on the shareholding reduction plan, confirming it is not a full report or announcement of a report publication.
2025-02-26 Chinese
关于米拉贝隆缓释片获国家药监局签发药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval and registration of a pharmaceutical product (米拉贝隆缓释片) by the National Medical Products Administration (NMPA) in China. It details the drug's registration certificate issuance, product information, impact on the company, and risk warnings. The document is short (1006 characters) and serves as a regulatory announcement about a product approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.